Edition:
India

Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

69.06USD
1:32am IST
Change (% chg)

$0.21 (+0.31%)
Prev Close
$68.85
Open
$68.99
Day's High
$69.23
Day's Low
$68.71
Volume
2,357,664
Avg. Vol
3,036,571
52-wk High
$69.23
52-wk Low
$52.83

Select another date:

Fri, Aug 17 2018

UPDATE 2-Japan's Eisai sets price tag of about $16,000 on liver cancer drug

* Wholesale price before discount is $15,970 for a 30-day supply

Merck profit beats, but Keytruda sales fail to impress

Merck & Co beat quarterly profit estimates on Friday as sales of its blockbuster drug Keytruda overtook rival Bristol-Myers Squibb's Opdivo, but that was not enough for investors who expected bigger gains in market share for the cancer therapy.

UPDATE 4-Merck profit beats, but Keytruda sales fail to impress

* Keytruda sales edge past rival Opdivo's, analysts' estimate

Merck's quarterly profit falls 12 pct

July 27 Drugmaker Merck & Co reported a 12.3 percent fall in quarterly profit on Friday, as research and development expenses rose.

Merck lowers prices of some drugs after Trump calls out industry

Merck & Co on Thursday announced price cuts to some of its medicines, including a 60 percent reduction to a hepatitis C treatment, after U.S. President Donald Trump criticized drugmakers for failing to help reduce healthcare costs for consumers.

UPDATE 1-Merck lowers prices of some drugs after Trump calls out industry

July 19 Merck & Co on Thursday announced price cuts to some of its medicines, including a 60 percent reduction to a hepatitis C treatment, after U.S. President Donald Trump criticized drugmakers for failing to help reduce healthcare costs for consumers.

Merck lowers prices of some drugs after Trump calls out industry

July 19 Merck & Co on Thursday announced price cuts to some of its medicines, including a 60 percent reduction to a little-used hepatitis C treatment, after U.S. President Donald Trump criticized drugmakers for failing to help reduce healthcare costs for consumers.

U.S. Supreme Court to hear Merck appeal over Fosamax suits

WASHINGTON The U.S. Supreme Court on Thursday agreed to hear Merck & Co's appeal of a lower court's ruling that revived hundreds of lawsuits accusing the company of failing to adequately warn patients of the risks of thigh bone fractures associated with its osteoporosis drug Fosamax.

CORRECTED-UPDATE 1-U.S. Supreme Court to hear Merck appeal over Fosamax suits

WASHINGTON, June 28 The U.S. Supreme Court on Thursday agreed to hear Merck & Co's appeal of a lower court's ruling that revived hundreds of lawsuits accusing the company of failing to adequately warn patients of the risks of thigh bone fractures associated with its osteoporosis drug Fosamax.

U.S. Supreme Court to hear Merck appeal over Fosamax suits

WASHINGTON, June 28 The U.S. Supreme Court on Thursday agreed to hear Merck & Co's appeal of a lower court's ruling that revived hundreds of lawsuits accusing the company of failing to adequately warn patients of the risks of thigh bone fractures associated with its osteoporosis drug Fosamax.

Select another date: